WO2010121600A3 - Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid- antagonisten - Google Patents

Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid- antagonisten Download PDF

Info

Publication number
WO2010121600A3
WO2010121600A3 PCT/DE2010/000453 DE2010000453W WO2010121600A3 WO 2010121600 A3 WO2010121600 A3 WO 2010121600A3 DE 2010000453 W DE2010000453 W DE 2010000453W WO 2010121600 A3 WO2010121600 A3 WO 2010121600A3
Authority
WO
WIPO (PCT)
Prior art keywords
opioid
particles
pharmaceutical composition
opioid antagonist
antagonist
Prior art date
Application number
PCT/DE2010/000453
Other languages
English (en)
French (fr)
Other versions
WO2010121600A2 (de
Inventor
Lars Holger Hermann
Original Assignee
Lars Holger Hermann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lars Holger Hermann filed Critical Lars Holger Hermann
Priority to EA201171271A priority Critical patent/EA201171271A1/ru
Priority to EP10723484A priority patent/EP2421515A2/de
Priority to AU2010238925A priority patent/AU2010238925A1/en
Priority to CA2759870A priority patent/CA2759870A1/en
Priority to US13/265,860 priority patent/US20120040009A1/en
Priority to JP2012506335A priority patent/JP2012524732A/ja
Publication of WO2010121600A2 publication Critical patent/WO2010121600A2/de
Priority to IL215813A priority patent/IL215813A0/en
Publication of WO2010121600A3 publication Critical patent/WO2010121600A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Abstract

Die Erfindung betrifft eine pharmazeutische Zusammensetzung, die erste Partikel und zweite Partikel umfasst, wobei die ersten Partikel mindestens ein Opioid oder ein pharmazeutisch annehmbares Salz davon umfassen, und die zweiten Partikel mindestens einen Opioid-Antagonisten oder ein pharmazeutisch annehmbares Salz davon umfassen, wobei die ersten und zweiten Partikel durch optisch erfassbare und/oder physikalische Eigenschaften nicht unterscheidbar sind, wobei die Freisetzung des Opioid- Antagonisten kontinuierlich über einen Zeitraum von 30 Minuten bis zu 8 Stunden nach oraler Verabreichung erfolgt, sowie eine diese enthaltende Darreichungsform zur peroralen Verabreichung. Weiterhin betrifft die Erfindung eine pharmazeutische Zusammensetzung, die ein Partikel mit dem Opioid und mit dem Opioid- Antagonisten mit oben genannter Freisetzungscharakteristik umfasst.
PCT/DE2010/000453 2009-04-22 2010-04-22 Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid- antagonisten WO2010121600A2 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EA201171271A EA201171271A1 (ru) 2009-04-22 2010-04-22 Фармацевтическая композиция в форме частиц с опиоидом и антагонистом опиоида
EP10723484A EP2421515A2 (de) 2009-04-22 2010-04-22 Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid- antagonisten
AU2010238925A AU2010238925A1 (en) 2009-04-22 2010-04-22 Particulate pharmaceutical composition having an opioid and an opioid antagonist
CA2759870A CA2759870A1 (en) 2009-04-22 2010-04-22 Particulate pharmaceutical composition with an opioid and an opioid antagonist
US13/265,860 US20120040009A1 (en) 2009-04-22 2010-04-22 Particulate pharmaceutical composition with an opioid and an opioid antagonist
JP2012506335A JP2012524732A (ja) 2009-04-22 2010-04-22 オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物
IL215813A IL215813A0 (en) 2009-04-22 2011-10-23 Pariticulate pharmaceutical composition with an opioid and an opioid antagonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009018474 2009-04-22
DE102009018474.0 2009-04-22

Publications (2)

Publication Number Publication Date
WO2010121600A2 WO2010121600A2 (de) 2010-10-28
WO2010121600A3 true WO2010121600A3 (de) 2011-10-27

Family

ID=42651253

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2010/000453 WO2010121600A2 (de) 2009-04-22 2010-04-22 Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid- antagonisten

Country Status (8)

Country Link
US (1) US20120040009A1 (de)
EP (1) EP2421515A2 (de)
JP (1) JP2012524732A (de)
AU (1) AU2010238925A1 (de)
CA (1) CA2759870A1 (de)
EA (1) EA201171271A1 (de)
IL (1) IL215813A0 (de)
WO (1) WO2010121600A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012087101A (ja) * 2010-10-21 2012-05-10 Holger Hermann Lars オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物
EP2606879A1 (de) 2011-12-21 2013-06-26 Hexal AG Multipartikuläre Tablette enthaltend ein Opioid
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
CN107205943A (zh) * 2014-12-08 2017-09-26 德威洛克制药有限公司 纳洛酮单剂和多层片剂
WO2020023486A1 (en) 2018-07-23 2020-01-30 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness and dyspnea

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058447A1 (en) * 2000-02-08 2001-08-16 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
WO2007082935A1 (de) * 2006-01-19 2007-07-26 Phoenux Ag Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen
EP1897544A1 (de) * 2006-09-05 2008-03-12 Holger Lars Hermann Opioid agonist und antagonisten Kombinationen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60013630T2 (de) * 1999-11-01 2005-09-15 John Cardiff Rhodes Arzneimittel zur behandlung von darmverstopfung und reizkolon
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058447A1 (en) * 2000-02-08 2001-08-16 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
WO2007082935A1 (de) * 2006-01-19 2007-07-26 Phoenux Ag Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen
EP1897544A1 (de) * 2006-09-05 2008-03-12 Holger Lars Hermann Opioid agonist und antagonisten Kombinationen

Also Published As

Publication number Publication date
AU2010238925A1 (en) 2011-12-15
JP2012524732A (ja) 2012-10-18
EA201171271A1 (ru) 2012-05-30
WO2010121600A2 (de) 2010-10-28
IL215813A0 (en) 2012-01-31
CA2759870A1 (en) 2010-10-28
EP2421515A2 (de) 2012-02-29
US20120040009A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
WO2010121600A3 (de) Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid- antagonisten
GEP20186839B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2009087634A3 (en) Methods and compositions for oral administration of insulin
WO2011084593A3 (en) Abuse-resistant formulations
WO2008107149A3 (de) Darreichungsform mit erschwertem missbrauch
WO2007150075A3 (en) Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
WO2013050539A3 (en) Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist
MX347753B (es) Formulaciones resistentes al abuso.
WO2012052169A3 (de) Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid-antagonisten
WO2008084698A1 (ja) タクロリムス徐放性医薬組成物
WO2009022354A3 (en) Modified dosage forms of tacrolimus
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
WO2009034541A3 (en) Controlled release pharmaceutical dosage forms of trimetazidine
WO2010123919A3 (en) Piperidine inhibitors of janus kinase 3
WO2008033351A3 (en) Multimodal abuse resistant and extended release formulations
WO2011041462A3 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
CA2725933A1 (en) Drug combinations comprising a dgat inhibitor and a ppar-agonist
WO2007050802A3 (en) Novel opioid antagonists
IL194871A (en) Compound linking to bir iap site, intermediate compound, process for compound preparation, method for making acceptable pharmaceutical salt, pharmaceutical preparation and use of compound for drug production
WO2009092129A8 (en) Delayed release pharmaceutical composition of duloxetine
WO2010141768A3 (en) Polycyclic antagonists of lysophosphatidic acid receptors
WO2011098582A3 (en) Novel crystalline forms of ivabradine hydrochloride
WO2009059048A3 (en) (+)-opioids and methods of use
WO2007150074A3 (en) Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
WO2008113901A3 (fr) Composition à libération prolongée de lévétiracetam et procédé de préparation.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10723484

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2012506335

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 13265860

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 215813

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2759870

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010723484

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: a201113307

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 12466

Country of ref document: GE

Ref document number: 201171271

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2010238925

Country of ref document: AU

Ref document number: 596574

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2010238925

Country of ref document: AU

Date of ref document: 20100422

Kind code of ref document: A